[go: up one dir, main page]

MX2018000175A - Compuestos de arilsulfonamida como inhibidores de la anhidrasa carbonica y su uso terapeutico. - Google Patents

Compuestos de arilsulfonamida como inhibidores de la anhidrasa carbonica y su uso terapeutico.

Info

Publication number
MX2018000175A
MX2018000175A MX2018000175A MX2018000175A MX2018000175A MX 2018000175 A MX2018000175 A MX 2018000175A MX 2018000175 A MX2018000175 A MX 2018000175A MX 2018000175 A MX2018000175 A MX 2018000175A MX 2018000175 A MX2018000175 A MX 2018000175A
Authority
MX
Mexico
Prior art keywords
compounds
inhibitors
carbonic
arilsulfonamide
anhidrasa
Prior art date
Application number
MX2018000175A
Other languages
English (en)
Other versions
MX387267B (es
Inventor
Zhang Zaihui
Original Assignee
Signalchem Lifesciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signalchem Lifesciences Corp filed Critical Signalchem Lifesciences Corp
Publication of MX2018000175A publication Critical patent/MX2018000175A/es
Publication of MX387267B publication Critical patent/MX387267B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30Oxygen or sulfur atoms
    • C07D233/32One oxygen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41661,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se describen en la presente los compuestos que tienen la siguiente estructura, útiles como inhibidores de la anhidrasa carbónica IX (CAIX) y XII, y particularmente útiles para reducir o eliminar metástasis, véase la Fórmula (I).
MX2018000175A 2015-07-01 2016-07-01 Compuestos de arilsulfonamida como inhibidores de la anhidrasa carbonica y su uso terapeutico. MX387267B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562187636P 2015-07-01 2015-07-01
PCT/US2016/040736 WO2017004543A1 (en) 2015-07-01 2016-07-01 Aryl sulfonamide compounds as carbonic anhydrase inhibitors and their therapeutic use

Publications (2)

Publication Number Publication Date
MX2018000175A true MX2018000175A (es) 2018-03-26
MX387267B MX387267B (es) 2025-03-18

Family

ID=56411955

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000175A MX387267B (es) 2015-07-01 2016-07-01 Compuestos de arilsulfonamida como inhibidores de la anhidrasa carbonica y su uso terapeutico.

Country Status (11)

Country Link
US (1) US10562859B2 (es)
EP (1) EP3317255B1 (es)
JP (1) JP6795525B2 (es)
KR (1) KR102637759B1 (es)
CN (1) CN107922345B (es)
AU (1) AU2016287587B2 (es)
BR (1) BR112018000065B1 (es)
CA (1) CA2991168C (es)
IL (1) IL256527B (es)
MX (1) MX387267B (es)
WO (1) WO2017004543A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS63755B1 (sr) * 2017-04-05 2022-12-30 Harvard College Makrociklično jedinjenje i njegova upotreba
KR20210000564A (ko) 2019-06-25 2021-01-05 공주대학교 산학협력단 신규 아만타딘 유도체 화합물 및 이의 용도
CN111233786B (zh) * 2020-02-04 2021-11-26 中国人民解放军军事科学院军事医学研究院 含五元杂环的苯磺酰胺类化合物及其制备方法和用途
CA3178176A1 (en) * 2020-06-02 2021-12-09 Fikrettin Sahin 2-(3-(2-methyl-6-(p-tolyl) pyridine-3-yl) ureido) benzenesulfonamide and derivatives as inhibitor of carbonic anhydrase ix for the treatment of cancer
TR202014185A2 (tr) * 2020-09-08 2022-03-21 Anadolu Ueniversitesi BAZI YENİ 4-(2-((5-(SÜBSTİTÜEAMİNO)-1,3,4-TİYADİAZOL-2-İL)TİYO)ASETİL)BENZENSÜLFONAMİD TÜREVLERİ ve SÖZ KONUSU TÜREVLERİN SENTEZİ İÇİN BİR YÖNTEM

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0211836A (pt) * 2001-08-10 2004-12-14 Pharmacia Corp Inibidor de anidrase carbÈnica
WO2008077597A1 (en) * 2006-12-22 2008-07-03 Novartis Ag 1-aminomethyl- l- phenyl- cyclohexane derivatives as ddp-iv inhibitors
EP2590938B1 (en) 2010-07-09 2017-06-07 Welichem Biotech Inc. Novel sulfonamide compounds for inhibition of metastatic tumor growth
CA2844783C (en) 2011-08-16 2019-10-29 Universite Laval Substituted 2-imidazolidinones and 2-imidazolones and their use in the treatment of cancer

Also Published As

Publication number Publication date
AU2016287587A1 (en) 2018-01-25
CA2991168A1 (en) 2017-01-05
US10562859B2 (en) 2020-02-18
HK1248228A1 (en) 2018-10-12
MX387267B (es) 2025-03-18
IL256527B (en) 2021-04-29
EP3317255A1 (en) 2018-05-09
AU2016287587B2 (en) 2020-04-30
CA2991168C (en) 2022-04-26
US20180201584A1 (en) 2018-07-19
CN107922345B (zh) 2021-03-23
JP2018519332A (ja) 2018-07-19
CN107922345A (zh) 2018-04-17
WO2017004543A1 (en) 2017-01-05
KR102637759B1 (ko) 2024-02-19
EP3317255B1 (en) 2021-09-01
KR20180023990A (ko) 2018-03-07
JP6795525B2 (ja) 2020-12-02
IL256527A (en) 2018-02-28
BR112018000065A2 (pt) 2018-09-11
BR112018000065B1 (pt) 2023-11-07

Similar Documents

Publication Publication Date Title
CY1120581T1 (el) Ενωσεις και μεθοδοι χρησης τους
CU20180059A7 (es) Compuestos inhibidores de la quinasa de unión a tank
CR20150462A (es) Inhibidores de erk y sus usos
UY35485A (es) Compuestos heterocíclicos y usos de los mismos
CO2018000631A2 (es) Compuestos bicíclicos como inhibidores de atx
CO2018000668A2 (es) Nuevos compuestos bicíclicos como inhibidores duales de atx/ca
MX2015011514A (es) Compuestos de heteroarilo y sus usos.
TN2017000544A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
CR20150524A (es) Compuestos de heteroarilo y sus usos
DOP2015000274A (es) Compuestos químicos
SV2016005180A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
CR20150436A (es) Nuevos octahidro-pirrolo[3,4-c]-pirrol y -piridina-fenilo
CR20140501A (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
CO2017011151A2 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
CR20150571A (es) Compuestos y composiciones terapéuticos
CR20180143A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
NI201500096A (es) Compuesto químicos
GT201600027A (es) Inhibidores de rorc2 y sus métodos de uso
UY35274A (es) Compuestos y métodos para tratar infecciones bacterianas
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
MX2018000175A (es) Compuestos de arilsulfonamida como inhibidores de la anhidrasa carbonica y su uso terapeutico.
CL2015002113A1 (es) Compuestos de azetidinloxifenilpirrolidina